Taylor Prince
Family · Guntersville, ALNPI 1669061461
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 691 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AbbVie at 27.5% of the total. 2025 is the largest year on record at $3,517, 2.5 times the $1,428 reported in 2021. Among family clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 691 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Novartis$1K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$868
- E.r. Squibb & Sons, L.L.C.$794
- Lilly USA, LLC$737
- plus $5K from 26 others
What the payments were for
- Food & beverage$13,41495%
- Education$6915%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 205 | $3,881 |
| Novartis | 89 | $1,489 |
| Sanofi | 48 | $1,052 |
| Regeneron Healthcare Solutions, Inc. | 36 | $868 |
| E.r. Squibb & Sons, L.L.C. | 41 | $794 |
| Lilly USA, LLC | 38 | $737 |
| LEO Pharma Inc. | 33 | $672 |
| Dermavant Sciences, Inc. | 18 | $666 |
| Johnson & Johnson | 25 | $579 |
| UCB, Inc. | 21 | $538 |
| Pfizer | 26 | $478 |
| Incyte Corporation | 14 | $472 |
| Sun Pharmaceutical Industries Inc. | 10 | $271 |
| Biofrontera Inc. | 13 | $257 |
| Amgen | 13 | $237 |
| Galderma Laboratories, L.p. | 20 | $210 |
| Arcutis Biotherapeutics, Inc. | 10 | $177 |
| Organon | 3 | $154 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Boehringer Ingelheim | 4 | $84 |
| Paratek Pharmaceuticals, Inc. | 5 | $70 |
| Mayne Pharma Commercial LLC | 3 | $64 |
| Genentech USA, Inc. | 3 | $58 |
| Fresenius Kabi USA, LLC | 2 | $36 |
| Verrica Pharmaceuticals Inc. | 2 | $36 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $32 |
| Botanix SB Inc | 1 | $20 |
| EPI Health, LLC | 1 | $19 |
| Mimedx Group, Inc. | 1 | $19 |
| Journey Medical Corporation | 1 | $17 |
| Almirall LLC | 1 | $17 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,106 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 49 | $996,172 |
| RinvoqUpadacitinib | 85 | $587,589 |
| Dupixent PenDupilumab | 98 | $352,027 |
| Cosentyx Unoready PenSecukinumab | 20 | $223,395 |
| Taltz AutoinjectorIxekizumab | 17 | $122,035 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 15 | $113,075 |
| OtezlaApremilast | 13 | $50,210 |
| Dupixent SyringeDupilumab | 11 | $41,163 |
| Clobetasol Propionate | 330 | $15,092 |
| Ketoconazole | 449 | $13,880 |
| JubliaEfinaconazole | 12 | $13,258 |
| Tacrolimus | 68 | $10,203 |
| Triamcinolone Acetonide | 297 | $5,696 |
| Fluorouracil | 63 | $5,230 |
| Betamethasone Dipropionate | 92 | $4,792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $3,881 | $587,58985 claims |
| AmgenOtezla | $237 | $50,21013 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $32 | $13,25812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.
Other family in Guntersville
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
- Julia BettsHuntsville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.